Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;2(10):e579-e580.
doi: 10.1016/S2665-9913(20)30287-3. Epub 2020 Aug 14.

The conundrum of interleukin-6 blockade in COVID-19

Corrado Campochiaro  1 , Lorenzo Dagna  1
Affiliations

The conundrum of interleukin-6 blockade in COVID-19

Corrado Campochiaro et al. Lancet Rheumatol. 2020 Oct.
No abstract available

PubMed Disclaimer

References

    1. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033–1034. - PMC - PubMed
    1. Cavalli G, De Luca G, Campochiaro C. Interleukin 1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. - PMC - PubMed
    1. De Luca G, Cavalli G, Campochiaro C. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2:e465–e473. - PMC - PubMed
    1. Della-Torre E, Campochiaro C, Cavalli G. Targeting IL-1, IL-6 or GM-CSF in COVID-19. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2020-218612. published online July 31. - DOI - PubMed
    1. Campochiaro C, Della-Torre E, Cavalli G. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Eur J Intern Med. 2020;76:43–49. - PMC - PubMed

LinkOut - more resources